An Associated Press investigation reveals that psychoactive industrial chemicals from manufacturing firms as well as pharmaceuticals from the drug industry are entering rivers and drinking water supplies in unregulated, unmeasured quantities.

Many of the substances in our most common medicines are manufactured in India and China. Some of these factories release large quantities of antibiotics and other pharmaceutical substances to the environment. There is an obvious risk of these releases leading to resistant bacteria.

Researchers at the University of Warwick and Astra Zeneca have found a new way to use solid-state NMR equipment to crack the secrets of hydrogen atoms and thus spot unwanted polymorphs in pharmaceuticals.

The American Cancer Society estimates that nearly 1.5 million new cases of cancer will be diagnosed this year. This crisis has caused the National Cancer Institute to establish a goal of eliminating suffering and death due to cancer by the year 2015.

Thousands of interesting new compounds have been discovered inside the bodies of marine sponges according to scientists speaking today at the Society for General Microbiology’s 161st Meeting.

Companies Will Jointly Conduct Phase III Development and Commercialization of DGAT-1 Inhibitor Compounds

IBM today announced the availability of an offering that will allow pharmaceutical companies to create an electronic certificate of authenticity (known as an electronic pedigree or ePedigree) for every drug that passes through the supply chain.

ARIAD and Merck & Co., Inc. Announce Global Collaboration to Jointly Develop and Commercialize AP23573 - ARIAD's Novel mTOR Inhibitor - for Cancer

Roche accesses Nobel Prize winning technology for drug discovery and development

Shanghai Century Acquisition Corporation (Amex: SHA), a special purpose acquisition corporation, announced today that it has entered into a definitive share purchase agreement to acquire 100 percent of the shares of privately-owned Sichuan Kelun Pharmaceutical Co., Ltd. (Kelun), China's largest producer of intravenous (IV) solution products.

Chemists are currently able to synthetically produce almost any compound, but they must typically resort to expensive, complex processes that can require dozens of individual steps. Such natural product syntheses have traditionally relied on the ubiquitous use of "protecting groups," which are extra compounds chemists use to shield reactive portions of a molecule during specific stages of a synthesis scheme.